HBV therapy may reduce liver cancer risk

Share this content:

the ONA take:

A recent study examined the effects of antiviral therapy on patients with hepatitis B virus (HBV) and researchers reported that the treatment appears to be associated with a lower risk of hepatocellular carcinoma.

Several forms of antiviral therapy were examined: interferon a-2b, lamivudine (3TC), pegylated interferon a-2a or a-2b, entecavir (Baraclude), tenofovir (Viread), telbivudine (Tyzeka), or adefovir (Hepsera). Twenty patients in the antiviral group later developed hepatocellular carcinoma, compared to 47 individuals in the non-therapy group.

The researchers stated that the antiviral therapy lowered incidence by approximately 60 percent. These findings imply an added benefit of the antiviral therapy—aside from the function of treating the virus at hand—of reducing long-tern risk of hepatocellular carcinoma. Additional studies are required to identify and record positive effects of this treatment in preventing liver cancer.

HBV therapy may reduce liver cancer risk
HBV therapy may reduce liver cancer risk
Antiviral treatment for hepatitis B virus (HBV) is associated with a lower risk of hepatocellular carcinoma, researchers reported. In a retrospective look at a cohort of people with chronic HBV, about three patients in 100 developed hepatocellular carcinoma over 5 years of follow-up, according to David Nerenz, PhD, of Henry Ford Health System in Detroit, and colleagues.
READ FULL ARTICLE From Medical Page Today
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs